-+ 0.00%
-+ 0.00%
-+ 0.00%

Protalix Biotherapeutics Announced A Collaboration With Secarna Pharmaceuticals For The Discovery Of Novel Antisense Oligonucleotide Therapies Against Multiple Targets For Rare Renal Indications, Deal Terms Were Not Disclosed

Benzinga·12/17/2025 11:53:13
Listen to the news
  • Partnership combines Protalix's rare disease and biologics expertise with Secarna's AI–powered OligoCreator® platform to jointly develop pharmaceutical candidates for rare renal indications
  • Protalix is granted an exclusive option to license any active compounds derived from the research for potential clinical development and commercialization